高脂血症是缺血性心脑血管疾病的危险因素之一,筛选有效的,不良反应少的降脂药是颇为重要的课题。洛伐他汀通过抑制肝脏HMG-CoA还原酶从而阻止内源性胆固醇合成,以达到调脂、降脂目的。我们于2008年1月至6月应用洛伐他汀片治疗42例高脂血症患者,验证其降脂疗效,现报告如下。1资 Hyperlipidemia is one of the risk factors of ischemic cardiovascular and cerebrovascular diseases. Screening effective lipid-lowering drugs with less adverse reactions is an important issue. Lovastatin can inhibit the synthesis of endogenous cholesterol by inhibiting the liver HMG-CoA reductase to achieve lipid-lowering and lipid-lowering. We in January 2008 to June lovastatin tablets treatment of 42 patients with hyperlipidemia, to verify the lipid-lowering efficacy, are as follows. 1 capital